Summary Red light (c. 630 nm) is almost universally used in tumour phototherapy as it is the most penetrating of the porphyrin excitation wavebands. However, measurements of tumour attenuation of light of different wavelengths and of the excitation spectrum of haematoporphyrin derivative in vitro suggested that green light might be more efficient than red in destroying thin tumours. Experimentally, we confirmed this for tumours up to -1.2mm thick, a depth exceeding that of most carcinomas-in-situ. The superiority of green light over red in terms of the illumination time required to produce equivalent depths of necrosis may extend to greater depths (3-4 mm) if the former is produced by an argon laser and the latter by an argon-pumped dye laser.
Tumour phototherapy depends on the ability of certain photosensitizing agents to localise in tumours, so that exposure of the tumour to sufficiently intense light of appropriate wavelength causes its rapid necrosis. The photosensitiser most widely used at present is "haematoporphyrin derivative" (HpD), a complex mixture of porphyrins (Bonnett et al., 1980 (Bonnett et al., , 1981 Berenbaum et al., 1982) . HpD is excited at a number of discrete wavebands, most intensely by violet light at 400-410nm (the Soret band), and with much less (and decreasing) intensity by bands at 500-505nm, 535-540nm, 565-575 nm and 620-635 nm. Only the red waveband (620-635nm) is used in tumour phototherapy as it has the greatest tissue penetration, an essential requirement in treating most human tumours, where light of adequate intensity may be needed through 1 cm or more of tissue.
However, the use of red light has disadvantages. First, generation of sufficiently intense red light requires (at present) use of a dye laser pumped by an ion laser, a costly and complicated arrangement. Second, the red waveband is the least efficient exciter of the porphyrin molecule.
Many human carcinomas do not demand use of highly penetrating light. For example, carcinoma-insitu is usually well under 1 mm thick in most sites, and many early invasive carcinomas are only a few mm thick. The question therefore arises as to whether illumination at wavebands other than the red, with less penetration but more efficient excitation, might be more suitable for such tumours. Here, we compare the effectiveness of tumour phototherapy at 405 nm (in the Soret band), 514.5 nm (the main output of the argon laser) and 630 nm (the wavelength used in clinical phototherapy).
Materials and methods Haematoporphyrin derivative
This was either (a) a 4mgml-P solution in 0.5% sodium hydrogen carbonate in PBS made from the solid, provided by Dr T.J. Dougherty, of the Roswell Park Memorial Institute or (b) the commercially available 5 mg ml-1 solution ("Photofrin", Oncology Research and Development, Inc., Cheektowaga, New York).
Excitation spectra in vitro
The fluorescence of HpD, lOpgml-' in '10% human serum in PBS was measured at 690 nm using the fluorimeter constructed by the Physical Chemistry group at the University of Amsterdam (Langelaar et al., 1969 ) using a small path length to avoid distortion of the spectrum by HpD absorption.
Light attenuation and scattering The tumour used for these measurements was the BA 1112 rhabdomyosarcoma (Reinhold, 1966) obtained from Prof. H.S. Reinhold, Radiobiological Institute, TNO, the Netherlands. It was grown subcutaneously in WAG-Rij rats and used 6 weeks after implantation, when it was -4cm in diameter. Measurements of attenuation and scattering were made 2-3 h after excision, using diffuse light from a 10cm integrating sphere, the interior of which was illuminated through a laterally placed aperture by light from a xenon arc used with a monochromator. Tumour slices 0.7-1.4mm thick were held between 0.2 mm thick glass slides over a 1 cm aperture at the top of the sphere. Diffuse transmittance through them was measured by a photodiode (W34, AEG Telefunken) and diffuse reflectance by a second diode placed under an aperture in the bottom of the sphere. Correction for reflection from the glass surfaces was made using equations (4) and (5) of Kottler (1960) .
Reflection and transmission were analysed in terms of absorption (A) and scattering (S) coefficients using Kubelka-Munk theory (cf Kottler (1960) , equations (1OH12)), as follows: Space irradiance Iz at tumour depth z is related to source intensity Io by
where rsp is the specular reflection coefficient of the tumour (typically 0.04-0.05), rd the diffuse reflectance from tumour thickness d and a is the attenuation coefficient given by = A(A + 2S) (Ishimaru, 1978) . With our data (Table I) The depth of tumour necrosis was measured 24 h after illumination as described previously (Berenbaum et al., 1982) . Table I shows relative excitation efficiencies for HpD in 10% serum of light at 630, 514.5 and 405 nm, and the values of A, S and a for tumour (rhabdomyosarcoma). A and S at 630 and 514.5nm were measured as described above. The value for A at 405nm was calculated as follows. At 405 and 514.5 nm, tissue absorption is dominated by its blood content, but this has a negligible effect at 630 nm (for oxygenated blood, A = 4cm-1 at 630nm, 105cm -1 at 514.5nm and 2600cm-l at 405nm (Ishimaru, 1978; van Gemert & Hulsbergen Henning, 1981) ). Thus, the fractional blood volume of the tumour may be estimated from the values for A at 514.5 and 530nm (Table I) as (4.5-2.2)/105= 0.022, and its absorption coefficient at 405nm as 0.022x2600=57.2cm-'. The value of S at 405nm was calculated using published data for wavelength dependence of scattering (Anderson & Parrish, Cg= A(A +2S) (Ishimaru (1978) , equations (10-6) and (10) (11) (12) (13) (14) .
Results

Photophysical parameters
dCalculation based on an estimated 2.2% (v/v) blood content of tumour and data for blood from Ishimaru (1978) and van Gemert & Hulsbergen Henning (1981) (see text). 'Extrapolated value using the wavelength dependence of dermal scattering (Anderson & Parrish, 1981) Table I ) agrees with data obtained by Eichler et al. (1977) for other tissues, which are in the range 55-70cm-1. Our value of 5.2cm-t for a for tumour at 630 nm is close to the value of 6.3 cm-1 found for a human lung carcinoma by Svaasand et al. (1981) . Further, measurements (not presented here) on a rat urothelial tumour used previously (Gijsbers et al., 1984) yielded results very similar to those of Table I . The data in Table I Figure 1 shows that there is a more or less linear relation between depth of necrosis and the logarithm of the light dose. Red light has the steepest dose-effect curve (slope 0.20 when dose is measured in natural logarithms) and the highest threshold for damage (-4.2Jcm 2), violet light has the shallowest curve (slope -0.023) and the lowest threshold (about 0.8 J cm-2) and green light is intermediate in both respects (slope 0.11 and threshold 2.5Jcm-2). Whereas red light is the most efficient of the three wavebands in causing tumour necrosis at depths exceeding -1.2+0.5mm, green light is more efficient at lesser depths. Violet light is the most efficient only at depths less than -0.2 +0.1mm.
Discussion
The relation between light dose and the extent of tissue damage is of great importance in tumour phototherapy. When tissues are illuminated in vivo, light intensity falls more or less exponentially with tissue depth (Eichler et al., 1977; Svaasand et al., 1981) . However, the rapid necrosis that ensues in photosensitised tissues, due to formation of chemically reactive singlet oxygen, does not. Instead, there is a zone of completely necrotic tissue and an abrupt transition to deeper tissue that appears histologically undamaged (Berenbaum et al., 1982, and Figure 2 ). This suggests that, for (Berenbaum, unpublished) . The depth of necrosis zn is that at which the threshold dose of singlet oxygen is produced, i.e., the depth at which attenuation reduces the light dose Do at the surface (where DO=Iot) to the threshold dose. This may be calculated from equation (2). That is, depth of necrosis should be proportional to the logarithm of light dose, a prediction borne out by Figure 1 . Equation (5) A comparison between the experimental doseeffect curves of Figure 1 and those calculated from Table I using equations (4) and (5) is shown in Figure 3 . Calculations were based on the experimentally measured threshold at 630nm, as this would be least affected by variations in tumour content of blood, whether oxygenated or not. The photophysical parameters (A and S) and depth of necrosis were perforce measured in two different tumours, but both are solid, homogeneous, and nonpigmented, and there was no a priori reason to expect their photophysical properties to differ 8- (4) and (5), using the relative excitation efficiencies and attenuation coefficients of Table 1 and the observed threshold of 4.2 J cm-2 at 630 nm. The experimentally determined curves of Figure 2 are inserted for comparison (dashed curves as in Figure 2 EA,2 Therefore, markedly. In fact, as mentioned above, a variety of normal and neoplastic tissues are found to have rather similar attenuation coefficients. -Considering the uncertainties in measuring the optical properties of tumours and the large variations inherent in producing and measuring tumour necrosis, we think that the level of agreement found between calculated and observed measurements (Figure 3 ) suggests that our overall approach is correct, although much refinement is needed, both theoretically and experimentally. In particular, Kubelka-Munk theory has limited validity for the collimated light we used to treat tumours, and other analytic methods (Svaasand et al., 1981) may be more appropriate.
Clinical implications Figure 1 shows that the dose-effect curves for tumour necrosis produced by red and green light respectively intersect at a tissue depth of -1.25 mm, green light being more efficient at lesser depths. However, these dose-effect curves do not fully reveal the potential advantage of green light for thin tumours with currently available light sources. Light at 630nm is at present generally produced by a dye laser pumped by an argon laser, but the conversion efficiency is at best 20-25%. More than half the argon output is in the green (514.5nm), the rest being mainly blue (488 nm). Therefore, 2-3 times as much power in the green may be obtained using the argon laser directly as may be obtained in the red from the dye laser. Thus, in terms of the illumination time needed to produce equivalent depths of necrosis, a more realistic comparison of the two wavebands would be made by transposing the dose-effect for green light to the left by a shift corresponding to a 2-to-3-fold reduction in dose. The curve for red light and the transposed curve for green would intersect at a depth of -3.3mm. An additional effect would be produced by the blue argon output (488nm), which has about the same (HpD) excitation efficiency as light at 514.5nm and nearly the same tissue penetrance. Thus our findings suggest that, for tumours of up to 3.3mm depth, and probably more, shorter illumination times would be entailed by using an argon laser directly rather than a red-emitting dye laser pumped by it. This depth encompasses that of tumours more extensive than carcinoma-in-situ, for example, many microinvasive carcinomas of the bladder (Farrow & Utz, 1982) . The argon laser is thus likely to be most useful where the tumour is thin and a large area requires illumination, for instance, in widespread carcinomain-situ of the bladder. Ideally, the whole bladder surface should be illuminated as local treatment is very likely to be followed by recurrence in the untreated area (Tsuchiya et al., 1983; Benson et al., 1983) , and delivery of an adequate dose of red light to the whole mucosa of the distended bladder, 2-300 cm2, with dye lasers now available may be prohibitively time-consuming. Use of argon laser with at least 2-3 times as much output at wavelengths that are more efficient than red in destroying superficial tumours may be preferable. Bellnier et al., (1984 Bellnier et al., ( , 1985 have independently drawn the same conclusion, after finding that green and red laser light at equal doses and dose-rates were equally effective in destroying thin (.2.5mm deep) tumours.
The question arises as to how far these findings may be extrapolated to man. Our mice (17-22g) received 40mgkg-' HpD, equivalent on a surface area basis to about 3mg kg-in man, a dose within the clinical range (2.5-5.0 mg kg-'). Such measurements as have been made suggest that 100-360 Jcm 2 of light at 630nm produces 5-10mm depth of necrosis in human tumours (Dougherty et al., 1985) . Extrapolation of the curve for 630nm in Figure 1 shows that, in our model, these doses would produce 6.5-9mm necrosis. Thus, agreement is surprisingly good.
The log-linear relation between light dose and depth of necrosis also has important implications. If the curve for red light in Figure 2 may be extrapolated, it suggests that it would require about 500 Jcm-2 at 630 nm to cause necrosis to a depth of 1 cm, which is feasible with current light sources. However, producing necrosis to a depth of -1.5 cm would require -6000 J cm 2, necessitating either impracticably long illumination times (a few hours) or light intensities at which thermal effects would predominate and selectivity due to photosensitisation would virtually disappear. Therefore progress in treating large tumours cannot depend solely on developing light sources of greater power but also on (a) developing methods for distributing light more uniformly throughout the tumour and (b) finding photosensitisers that are excited efficiently at longer and more penetrating wavelengths, thus in effect increasing the slope of the tumour necrosis dose-effect curve. 
